Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma (COMBI-AD)
Source: View publication →
In patients with resected BRAF V600-mutant stage III melanoma, 12 months of adjuvant dabrafenib plus trametinib significantly improved relapse-free survival and distant metastasis–free survival compared to placebo, though long-term overall survival did not reach statistical significance.
Key Findings
Study Design
Study Limitations
Clinical Significance
The COMBI-AD trial established BRAF/MEK inhibition as an effective adjuvant strategy for patients with BRAF V600-mutated resected stage III melanoma, providing a durable relapse-free survival benefit. While adjuvant immunotherapy is currently the preferred standard in many cases, this trial remains a foundational study for targeted therapy in the adjuvant setting.
Historical Context
Prior to COMBI-AD, adjuvant therapy options for melanoma were limited and often associated with significant toxicity with minimal efficacy. The success of targeted BRAF/MEK inhibition in metastatic disease prompted the investigation into the adjuvant setting to delay recurrence following surgical resection, leading to the first FDA approval of a targeted therapy combination for this indication in 2018.
Guided Discussion
High-yield insights from every perspective
Dabrafenib and trametinib target the MAPK pathway at different levels. Explain the mechanism of 'paradoxical activation' that occurs with BRAF-inhibitor monotherapy and how the addition of a MEK inhibitor like trametinib mitigates this risk.
Key Response
In cells with wild-type BRAF (such as normal skin cells), BRAF inhibitors can paradoxically activate the MAPK pathway by inducing BRAF-CRAF dimerization, leading to secondary cutaneous squamous-cell carcinomas. Adding a MEK inhibitor (trametinib) downstream of this interaction blocks the resulting signal, significantly reducing the incidence of these secondary skin cancers while increasing the blockade of the pathway in V600-mutant melanoma cells.
A patient starting adjuvant dabrafenib plus trametinib develops a high fever (39.5°C) and chills during the second month of therapy. According to the COMBI-AD protocol and standard management, what is the appropriate first-line intervention for this specific toxicity?
Key Response
Pyrexia is the most common adverse event (occurring in >60% of patients). The standard management involves immediate interruption of both dabrafenib and trametinib at the first sign of fever. Once the patient is afebrile for 24 hours, the drugs can be resumed, often at the same dose for the first episode, though recurrent or severe pyrexia may require dose reductions or prophylactic use of low-dose corticosteroids.
In the COMBI-AD 5-year follow-up, the Relapse-Free Survival (RFS) curve appears to plateau after approximately 3 years. How does this 'tail of the curve' compare mechanistically and clinically to the RFS data seen with anti-PD-1 immunotherapy (e.g., KEYNOTE-054), and what does this suggest about the potential for 'cure' with targeted therapy?
Key Response
Historically, targeted therapy was thought to only delay recurrence, while immunotherapy offered a durable 'plateau.' However, COMBI-AD demonstrated a persistent RFS benefit (52% at 5 years) even after treatment cessation at 12 months, suggesting that a subset of patients may be cured by targeted therapy. Unlike immunotherapy, which modulates the immune system for a lasting effect, the durability of BRAF/MEK inhibition post-treatment likely reflects the eradication of microscopic disease during the one-year window.
The final OS analysis of COMBI-AD showed a hazard ratio for death of 0.80, but it did not meet the pre-specified P-value for statistical significance (0.0001) due to the stringency of the hierarchy. In clinical practice, does this lack of formal OS significance change the standard of care, and how do you reconcile this with the 48% reduction in the risk of relapse?
Key Response
Despite missing the very strict alpha threshold for OS, the clinical benefit remains profound. The lack of OS significance is likely due to 'crossover' or the high efficacy of subsequent-line therapies (immunotherapy and BRAF/MEK inhibitors) in the placebo group upon recurrence. Most clinicians still view the 12-month adjuvant course as a standard-of-care option because preventing recurrence (RFS) and distant metastasis (DMFS) are highly valued clinical endpoints in melanoma.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
Critically analyze the statistical impact of post-progression therapy on the COMBI-AD Overall Survival (OS) results. What alternative statistical models could have been employed to estimate the true survival benefit of the adjuvant intervention had the control group not received subsequent active treatments?
Key Response
Post-progression survival (PPS) significantly dilutes the treatment effect on OS in modern melanoma trials. Researchers could use 'Rank-Preserving Structural Failure Time' (RPSFT) models or 'Inverse Probability of Censoring Weighting' (IPCW) to adjust for treatment crossover. These models would likely show a more pronounced survival benefit by estimating the counterfactual outcome of a placebo group that never received subsequent BRAF/MEK or PD-1 inhibitors.
As a reviewer, what concerns would you raise regarding the generalizability of the COMBI-AD results to the Stage IIIA population, specifically those with <1mm of nodal tumor burden as defined by the AJCC 8th edition?
Key Response
The COMBI-AD trial utilized AJCC 7th edition criteria and required a minimum of 1mm of nodal tumor burden for Stage IIIA patients. The AJCC 8th edition now includes smaller nodal deposits. Therefore, the very low-risk Stage IIIA patients (e.g., <0.1mm sentinel lymph node metastasis) might be over-treated by a 12-month regimen that has a high rate of grade 3/4 adverse events, making the benefit-risk ratio less favorable for this sub-population.
Current NCCN and ESMO guidelines list both BRAF/MEK inhibitors and anti-PD-1 antibodies as Category 1/Level A options for Stage III BRAF-mutant melanoma. What specific patient factors or trial data elements would justify prioritizing one class over the other in a formal update?
Key Response
Prioritizing one would require direct head-to-head data, which is currently lacking. However, guidelines should specify that targeted therapy (COMBI-AD) is preferred for patients with contraindications to immunotherapy (e.g., severe autoimmune disease) or those prioritizing avoiding permanent immune-related adverse events (like Type 1 diabetes or hypophysitis), whereas immunotherapy may be preferred for patients who wish to avoid the high daily toxicity burden and frequent monitoring associated with dabrafenib/trametinib pyrexia.
Clinical Landscape
Noteworthy Related Trials
BRIM-3 Trial
Tested
Vemurafenib
Population
Patients with previously untreated BRAF V600E-mutated metastatic melanoma
Comparator
Dacarbazine
Endpoint
Overall survival and progression-free survival
CheckMate 067 Trial
Tested
Nivolumab plus ipilimumab or nivolumab monotherapy
Population
Patients with previously untreated stage III or IV melanoma
Comparator
Ipilimumab monotherapy
Endpoint
Progression-free survival
EORTC 18071 Trial
Tested
Ipilimumab
Population
Patients with resected stage III cutaneous melanoma
Comparator
Placebo
Endpoint
Recurrence-free survival
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis